Almado, Inc.

Almado, Inc.

TTSE:4932
740.00
JPY
+10.00
(+1.37%)
7.39BMarket Cap
Nov 13Next Earn
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
2026 Y
TTM
Revenue per Share
228.54
314.42
577.88
453.43
532.69
671.92
791.07
917.98
1,094.43
- -
Basic EPS, GAAP
17.02
27.69
64.97
36.69
57.81
60.29
72.98
70.43
56.07
- -
Free Cash Flow per Basic Share
-2.75
7.14
17.95
63.89
24.87
72.52
87.58
-28.15
80.37
- -
Dividend per Share
- -
37.62
- -
- -
- -
41.15
65.44
70.07
64.9
- -
Book Value per Share
117.62
107.69
161.77
231.03
268.93
243.09
203.82
203.01
196.55
- -
Tangible Book Value per Share
114.32
104.45
158.66
227.57
265.84
240.37
201.75
200.2
191.93
- -
Basic Weighted Avg Shares
12
12
10
10
10
10
10
9
9
9
Sales/Revenue/Turnover
2,754
3,789
5,796
4,548
5,365
6,529
7,539
8,477
10,119
- -
Operating Margin (%)
20.76
12.13
16.99
11.59
15.58
12.74
12.74
11.16
6.77
- -
Depreciation Expense
24
25
28
21
17
16
16
32
26
- -
Net Income, GAAP
205
334
652
368
582
586
695
650
518
- -
Effective Tax Rate (%)
32.48
27.14
33.69
31.48
30.4
30.02
27.8
30.56
24.84
- -
Profit Margin (%)
7.45
8.81
11.24
8.09
10.85
8.97
9.23
7.67
5.12
- -
Working Capital
1,606
1,419
1,785
2,147
2,528
2,197
1,769
1,640
1,589
- -
LT Debt
341
280
- -
3
2
1
- -
4
3
- -
Total Equity
1,417
1,298
1,949
2,317
2,688
2,332
1,884
1,874
1,819
- -
Return on Invested Capital (%)
- -
18.21
31.88
14.48
20.7
18.84
22.1
18.11
12.73
- -
Return on Capital (%)
- -
19.41
35.21
16.52
22.61
20.83
24.21
19.24
13.82
- -
Return on Common Equity (%)
- -
24.58
40.14
17.25
23.26
23.34
32.99
34.62
28.08
- -

Capital Structure

JPY

•

in mil. unless spec.
Sep'26
Mar'26
Jun'27
ST Debt
3,051
2,001
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
4
3
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
9
9
9
Market Capitalization
10,234
7,393
5,950

Working Capital

JPY

•

in mil. unless spec.
Sep'26
Mar'26
Jun'27
Total Current Assets
4,480
4,238
- -
Cash, Cash Equivalents & STI
1,281
1,623
- -
Accounts Receivable, Net
763
628
- -
Inventories
1,614
1,716
- -
Total Current Liabilities
4,082
2,649
- -
Payables & Accruals
- -
- -
- -
ST Debt
3,051
2,001
- -
Deferred Revenue
- -
- -
- -

Growth Rates

JPY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
-3.99%
-2.94%
Free Cash Flow
- -
-75.63%
-385.82%
Net Income, GAAP
- -
10.16%
-20.3%
Sales/Revenue/Turnover
- -
17.39%
19.36%
Total Cash Common Dividend
- -
- -
-7.26%

Quarterly Revenue

JPY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
- -
- -
- -
- -
8,477
2026
- -
- -
- -
- -
10,119
2027
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

JPY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
- -
- -
- -
- -
70.43
2026
- -
- -
- -
- -
56.07
2027
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

JPY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
- -
- -
- -
- -
70.07
2026
- -
- -
- -
- -
64.9
2027
- -
- -
- -
- -
- -

Company Description

CEO
Shiro Hoshina
Full Time Employees
93
Sector
Consumer non-durables
Industry
Household/Personal care
Address
Ryoka Building Tokyo TY Japan 103-0022
IPO Date
Jun 24, 2021
Business
Almado Inc (TSE:4932) plans, develops, sells cosmetics, supplements, and quasi-drugs derived primarily from eggshell membrane materials in Japan, with all production outsourced. Core products include skincare such as whitening serum, moisturizing eggshell membrane serum, wrinkle-reducing and firmness-enhancing creams, facial cleansing with electrolyzed water, brightening lotions, hyaluronic acid spicules, and beauty drinks; hair growth supplements; and other beauty foods under brands including TO-II, Ode series, CELLULA, Type III, AMF, and Almado La Dina; the company also provides original equipment manufacturing (OEM) services and wholesale. It operates through television shopping channels such as QVC, external indirect sales to drug stores, hairdressers, and mail order firms, and in-house direct sales via proprietary and third-party e-commerce sites, targeting individual consumers seeking health and beauty solutions based on eggshell membrane biotechnology. Founded in 2000 and headquartered at 3-6-18 Kyobashi, 8F Tokyo Tatemono Kyobashi Building, Chuo-ku, Tokyo, Japan, Almado maintains a focused eggshell membrane healthcare segment with approximately 71 employees. Recent major changes encompass strategic ownership shifts including CBC Co Ltd's acquisition of an additional 10.26% stake in 2022 from Ant Capital Partners-managed funds, alongside ongoing research advancements and product promotions through key channels without noted new partnerships, funding rounds, or expansions in 2024-2025.